This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.
These guidelines offer principles and best practices for the licensing of genetic inventions used for the purpose of human health care.
This book evaluates the performance of the Finnish health system in terms of quality of care, efficiency, fiscal sustainability and equity.
While many countries have invested in the production of health technology assessment, evidence about its use in decision making is limited. This report analyses the barriers to, and facilitators of, evidence-based decision making in OECD health-care systems.
This workshop brought together a wide range of stakeholders, including officials of regulatory agencies, representatives of relevant regional or international organizations, researchers, patients’ organizations and representative from industry.
Long-term care is a cross-cutting policy issue that brings together a range of services for persons who are dependent on help with basic activities of daily living. How do governments in OECD countries respond to this growing demand? What has been done to improve access to long-term care, improve quality of services and make care affordable?
This paper provides an inventory of biotechnology data collection in India, including an assessment of how the need for biotechnology-related statistics is being addressed. It also presents an overview of the status of biotechnology in India, with a focus on the agricultural and health sectors.
This framework is intended to provide the basis for statistical compilation work within OECD member countries and those non-member countries wishing to adopt the standards.
This document sets out the provisional, single definition and list-based definitions of biotechnology.